Abstract:Introduction: Overactivation of the type I interferon (IFN) signature has been observed in several systemic autoimmune conditions, such as Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA). Impaired control of Interferon-Responding Genes (IRGs) expression by their regulatory mechanisms, including Interferon Regulatory Factors (IRFs), may underlie these findings and it may explain the heterogeneity observed among these conditions. In the present study we aimed to evaluate the associations between IRF4 gene expression and those of IRGs in SLE and RA patients to gain insight about its links with the IFN signature as well as to explore the potential clinical relevance of these associations. Methods: The gene expression of IRF4 and IRGs (IFI44, IFI44L, IFI6, and MX1) in peripheral blood was analyzed in 75 SLE patients, 98 RA patients, and 28 healthy controls. A group of 13 biological-naïve RA patients was prospectively followed upon TNFα-blockade. The associations among IRF4 and IRGs were evaluated by principal component analyses (PCA), correlations and network analyses. Publicly available datasets were used for replication. Results: A broad activation of IRGs was observed in autoimmune patients, although certain heterogeneity can be distinguished, whereas IRF4 was only upregulated in RA. The differential expression of IRF4 in RA was then confirmed in publicly available gene expression datasets. PCA revealed different associations among IRF4 and IRGs in each condition, which was later confirmed by correlation and network analyses. Cluster analysis identified 3 gene expression signatures on the basis of IRF4 and IRGs expression which were differentially used by SLE and RA patients. Cluster III was associated with markers of disease severity in SLE patients. Cluster II, hallmarked by IRF4 upregulation, was linked to clinical stage and mild disease course in RA. TNFα-blockade led to changes in the association between IRF4 and IRGs, whereas increasing IRF4 expression was associated with a good clinical outcome in RA. Conclusions: The differential expression of IRF4 and IRGs observed in SLE and RA can delineate gene expression signatures associated with clinical features and treatment outcomes. These results support a clinically-relevant phenomenon of shaping of the IFN signature by IRF4 in autoimmune patients.

RelB-deficient autoinflammatory pathology presents as interferonopathy, but in mice is interferon-independent

Inherited human RelB deficiency impairs innate and adaptive immunity to infection

Role of the NF-κB Family Member RelB in Regulation of Foxp3+ Regulatory T Cells in Vivo.

Single Cell Transcriptomic Dissection of Virus Induced Immunopathology in Interferon Gamma Receptor Null Mice

Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options

Rare and novel RELA variants are common in systemic autoimmunity

Aberrant inflammatory responses to type I interferon in STAT2 or IRF9 deficiency

Genomic View of IFN-α Response in Pre-Autoimmune NZB/W and MRL/lpr Mice

Aberrant RNA sensing in regulatory T cells causes systemic autoimmunity

Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus

Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice

AIM2-Like Receptors Positively and Negatively Regulate the Interferon Response Induced by Cytosolic DNA

The Transcription Factor RelB Restrains Group 2 Innate Lymphoid Cells and Type 2 Immune Pathology in Vivo.

IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Interferon target-gene expression and epigenomic signatures in health and disease

FRI0263 Activation of the interferon pathway is dependent upon autoantibodies in african american sle patients, but not in european-american sle patients

Crucial Role for TNF Receptor-Associated Factor 2 (TRAF2) in Regulating NFκB2 Signaling That Contributes to Autoimmunity.

Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B Cell Responses to Extracellular Self-DNA

Transcription factor c-Rel plays a crucial role in driving anti-CD40-mediated innate colitis

Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients

Type I IFN Drives Experimental Systemic Lupus Erythematosus by Distinct Mechanisms in CD4 T Cells and B Cells